Pharmafile Logo
Pharmafocus logo
Advanced Search

Pancreatic cancer

Showing 12 posts of 27 posts found.

cancer_cells

Breakthrough treatment for pancreatic cancer doubles survival rates

January 25, 2017
Research and Development CRUK, Cancer Research UK, Pancreatic cancer

Research led by Liverpool University and funded by Cancer Research UK has shown that a combination treatment of two off-patent …

News
shire_image

Shire receives positive EU opinion for pancreatic cancer drug

July 25, 2016
Research and Development, Sales and Marketing CHMP, EU, Pancreatic cancer, Shire

Shire has announced that the EU regulator’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion …

News
stocks3

Aduro’s pancreatic cancer immunotherapy fails Phase II trials; shares plunge

May 17, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Aduro Biotech, Pancreatic cancer, Stock, drug trial, markets

Shares in Aduro Biotech (Nasdaq: ADRO) dropped to closed down over 16% after the company said mid-stage trials of its …

News
incyte

Incyte to stop Jakafi pancreatic, colorectal cancer drug trials

February 11, 2016
Research and Development Incyte, Jakafi, Jakavi, Novartis, Pancreatic cancer, colorectal cancer

Incyte said today that it is terminating its JANUS clinical trial programme testing blood cancer drug Jakafi in solid tumours …

News
Merck image

Late-stage failure for Merck and Threshold cancer drug

December 7, 2015
Research and Development, Sales and Marketing Merck, Pancreatic cancer, Threshold Pharmaceuticals, evofosfamide, late-stage failure, phase III, sarcoma

Merck and its development partner Threshold Pharmaceuticals say they will not pursue regulatory approval for evofosfamide in advanced soft tissue …

News
Researcher

Scientists make possible pancreatic cancer discovery

November 18, 2015
Research and Development Pancreatic cancer

Cancer researchers say they have discovered a potential new method of treatment for pancreatic cancer that could improve survival rates.  …

News
Phase III trial

FDA approves new therapy for pancreatic cancer

October 30, 2015
Medical Communications, Sales and Marketing FDA, Pancreatic cancer

The FDA has approved drug a pancreatic cancer drug, Onivyde, which has produced significant overall survival rates in an international …

News
Abraxane

NICE says Celgene’s Abraxane is ‘too expensive for pancreatic cancer’

September 17, 2015
Sales and Marketing Abraxane, Celgene, NICE, Pancreatic cancer

NICE has decided not to recommend Abraxane (nab-paclitaxel) by Celgene in combination with gemcitabine for adults with metastatic pancreatic cancer.In …

News
Astellas logo

Cancer Research UK and Astellas announce partnership

August 8, 2014
Medical Communications, Research and Development, Sales and Marketing Astellas, CRUK, Canncer, Pancreatic cancer

Cancer Research UK and its commercial arm, Cancer Research Technology (CRT) have announced they are joining forces with Astellas in …

News

Novartis/Incyte’s Jakavi may help fight pancreatic cancer

August 22, 2013
Research and Development, Sales and Marketing Incyte, Jakafi, Novartis, Pancreatic cancer, Xeloda

News
Novartis Afinitor

Afinitor expands European licence

September 5, 2011
Sales and Marketing Afinitor, Novartis, Pancreatic cancer

Novartis’ Afinitor has made further strides in the EU with an approval for use in patients with advanced pancreatic neuroendocrine …

News
Amgen HQ

Amgen aims for oncology expansion and a wider denosumab license

January 12, 2011
Research and Development AMG- 479, AMG-386, Amgen, Cancer, Pancreatic cancer, denosumab, motasenib

Amgen is seeking to increase the use of its bone drug denosumab and further its reach into the oncology market, …

News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026